. Mitogen-activated protein kinase (MAPK) signaling. GPCR, G protein-coupled receptor; MLK, Mixed lineage kinase; TAK, TGF-β activated kinase; ASK, Apoptosis signalregulating kinase.
ERK1/2
ERK1 and ERK2 are isoforms of the classical MAPK. Both ERK1 and ERK2 are activated by MAP/ERK kinase 1 (MEK1) and MEK2, which are members of the MAPKK family (Nishimoto and Nishida, 2006) . After stimulation by a variety of mitogens, including peptide growth factors, MEK1/2 is activated by MAPKKK-mediated phosphorylation. These MAPKKKs include Raf and Mos. MEK1/2 then phosphorylates threonine and tyrosine residues in the Thr-Glu-Tyr (TEY) sequence of ERK1/2, thereby activating it. Activated ERK1/2 phosphorylates many substrates, including transcription factors, such as Elk1 and c-Myc, and protein kinases, such as ribosomal S6 kinase (RSK). Subsequently, immediate early genes, such as c-Fos, are induced. At the cellular level, ERK1/2 regulates cell cycle progression, proliferation, cytokinesis, transcription, differentiation, senescence, cell death, migration, GAP junction formation, actin and microtubule networks, and cell adhesion (Ramos, 2008) . Owing to its role in cellular biology, ERK1/2 is a prominent player in physiological settings, influencing the immune system and heart development and participating in the cellular response to many hormones, growth factors, and insulin. The ERK1/2 pathway is activated not only by growth factors, serum, and phorbol esters, but also by G protein-coupled receptors (GPCR), cytokines, microtubule disorganization, and other stimuli (Goldsmith and Dhanasekaran, 2007; McKay and Morrison, 2007; Raman et al., 2007) . Prototypically, binding of growth factors (such as FGF) to their respective receptor tyrosine kinases (RTK) activates Ras, which recruits and activates Raf (MAP3K) at the plasma membrane. Once activated, Raf phosphorylates and activates MEK1/2. MEK1/2, in turn, activates ERK1/2 by phosphorylation of the Thr and Tyr residues in the conserved TEY motif within its regulatory loop. Activated ERK1/2 can phosphorylate downstream proteins, including many transcription factors, in the cytoplasm or nucleus.
ERK5
ERK5, also known as big MAP kinase 1 (BMK1), is twice the size of the other MAPKs (Lee et al., 1995a; Zhou et al., 1995) . Since it is activated by oxidative stress and hyperosmolarity, ERK5 was initially documented as a MAPK family member activated by stress stimuli (Abe et al., 1996) . Subsequently, ERK5 was also shown to be activated in response to serum, one of the well-known activators of ERK1/2 (Kato et al., 1997) . Once activated, ERK5 exerts its kinase activity on a number of other protein kinases and transcription factors in both the cytosol and the nucleus. Furthermore, unlike other MAPKs, ERK5 has been shown to function directly as a transcriptional activator (Akaike et al., 2004; Kasler et al., 2000) . Diverse biological roles of ERK5, including cell survival, differentiation, proliferation, and growth, have also been identified. ERK5 is reported to play a physiological role in neuronal survival, endothelial cell response to sheer stress, prostate and breast cancer, cardiac hypertrophy, and atherosclerosis Nishimoto and Nishida, 2006; Wang and Tournier, 2006) . Nerve growth factor, Ang II, high glucose, and other stimulators of ERK1/2 can also increase ERK5 activity (Kamakura et al., 1999) . Similar to the ERK1/2 pathway, the MEK-ERK5 pathway is blocked by MEK inhibitors (Kamakura et al., 1999) . Thus, there are similarities between the activation modes and functions of the ERK5 and ERK1/2 pathways. However, recent studies have also identified some distinctive features of the ERK5 and ERK1/2 pathway (Mulloy et al., 2003; Squires et al., 2002) .
MAPKs in GN
A number of former studies have reported that the MAPK pathway plays a crucial role in the development of renal diseases. Bokemeyer et al. reported that ERK1/2 activation occurs in the rat Thy-1 model of mesangioproliferative nephritis, and that inhibition of the ERK1/2 pathway results in a significant reduction in mesangial cell proliferation in this model (Bokemeyer et al., 2000; Bokemeyer et al., 2002) . The glomerular ERK1/2 was maximally activated on day 6 and represents a putative mediator of the proliferative response in mesangioproliferative GN. In addition, ERK1/2 activation in human glomerulopathies is associated with cell proliferation, histological lesions, and renal dysfunction (Masaki et al., 2004) . Thus, these studies showing ERK activation in damaged glomeruli raise the possibility that ERK1/2 is an important signal molecule for acute inflammation-induced cellular proliferation in GN. ERK5 was originally shown to be activated by stress stimuli or serum (Kamakura et al., 1999; Kato et al., 1997) . Other stimuli, such as oxidative stress, Ang II, and high glucose, can also activate ERK5 in various cell types (Kato et al., 2000) . Previous reports have demonstrated that ERK5 is activated in the glomeruli of diabetic nephropathy rat models, but not in normal control rats. High glucose also induces ERK5 activation in cultured MCs in vitro (Suzaki et al., 2004) . It was suggested that ERK5 might be involved in glomerular injury during the pathogenesis of diabetic nephropathy.
Animal experiments
We have established a progressive model of mesangioproliferative GN, as previously described (Nakamura et al., 1999) . Briefly, rats (n = 36) were uninephrectomized, and, 1 week later, administered with a single intravenous injection of 2 mg of nephritogenic antiThy-1 monoclonal antibody 1-22-3. This monoclonal antibody recognizes a critical epitope of the Thy-1.1 molecule on the mesangial cell surface. Upon binding to its epitope, the antibody induces severe complement-dependent mesangial cell injury. The injection of monoclonal antibody 1-22-3 into uninephrectomized rats induced chronic progressive glomerulosclerosis with marked proteinuria. Control rats (n = 6) only received a vehicle. Six rats were sacrificed at each time point (days 3, 7, 14, 28, and 56 after the monoclonal antibody injection). In addition, 6 rats were sacrificed as baseline controls (0 h) prior to the injection of monoclonal antibody 1-22-3, and 5 rats (Nx group) were injected with PBS one week post-uninephrectomy and sacrificed on day 56 after the injection. The right kidney of each rat was removed, immediately fixed in 10% buffered-formalin, embedded in paraffin, cut into 4-m sections, and stained with periodic acid-Schiff (PAS) reagent. The mean glomerular cell number, which was based on the total glomerular cell count per glomerular cross section after PAS staining, was calculated for 30 glomeruli/kidney. A pathologist, who was blinded to the other findings, semiquantitatively analyzed the glomerulosclerosis score. The percentage of each glomerulus occupied by the mesangial matrix was estimated and assigned a code, according to the following system: 0, 0%; 0.5, 1-5%; 1, 5-25%; 2, 25-50%; 3, 50-75%; and 4, >75%. Frozen sections (3 m) were fixed in acetone, incubated with a rabbit anti-phospho-ERK5 antibody at 4ºC overnight, and then incubated with a FITC-conjugated donkey anti-rabbit IgG antibody. To evaluate the level of glomerular staining with each antibody, we performed a semi-quantitative analysis, according to the following scoring system: 0, diffuse, very weak or no mesangial staining; 1+, 1-25% of glomerular tufts exhibit focal increases in mesangial staining; 2+, 25-50% of glomerular tufts exhibit strong mesangial staining; 3+, 50-75% of glomerular tufts exhibit strong mesangial staining; and 4+, >75% of glomerular tufts exhibit strong mesangial staining. For each kidney section, 30 glomeruli were selected at random and evaluated in a blinded fashion by the same pathologist. The mean value per section was then calculated. Formalin-fixed tissue sections (3 m) were deparaffinized with xylene and rehydrated through a graded series of ethanol. Endogenous peroxidase was blocked by incubation with hydrogen peroxide, and the samples were heated at 121ºC for 15 minutes in 0.01 mol/L citrate buffer (pH 6.0) for antigen retrieval. Next, the sections were incubated at 4ºC for 24 hours with an anti-phospho-ERK1/2 antibody diluted in PBS containing 1% BSA. After washing with PBS, the sections were incubated with a biotinylated secondary antibody and avidin-biotin-peroxidase complex (ABC Elite; Vector Laboratories, Burlingame, CA), and developed with 3,3'-diaminobenzidine. Each section was counterstained with Mayer's hematoxylin, dehydrated, and coverslipped. The phospho-ERK1/2-positive cells in 30 full-size glomeruli were counted, and the mean value was calculated.
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ERK1/2 and ERK5 expression in rat models of progressive GN
Early induction of ERK1/2 phosphorylation was detected on days 3 and 7 of GN. A significant increase in phosphorylated ERK1/2 was not seen in the late phase of GN. In contrast to the time course of glomerular ERK1/2 phosphorylation, glomerular phospho-ERK5 expression was very weak on day 3. However, the level of this expression increased in the expanded mesangial area by day 7, and dramatically increased in a typical mesangial pattern by days 28 and 56 (Fig. 2) . The level of glomerular phospho-ERK5 expression closely paralleled the glomerulosclerosis score during the course of chronic anti-Thy-1-induced GN (P < 0.05). Treatment of GN rats with an Ang II type 1 receptor blocker (ARB) resulted in a significant decrease in phospho-ERK5 expression, accompanied by remarkable histological improvement. We have also previously reported that increased ERK5 phosphorylation is associated with MC proliferation and ECM accumulation in the glomeruli of 52-week-old OLETE rats, a model of type 2 diabetic mellitus (DM) (Suzaki et al., 2004) . Bokemeyer et al. demonstrated that glomerular ERK1/2 is maximally activated on day 6 and that blocking
Renin-Angiotensin System Activation and Extracellular Signal-Regulated Kinases in Glomerulonephritis 209 the ERK1/2 pathway using a specific inhibitor results in a significant reduction in mesangial cell proliferation in mesangioproliferative GN (Bokemeyer et al., 2000; Bokemeyer et al., 2002) . Thus, these studies demonstrating ERK activation in damaged glomeruli suggest the possibility that ERK1/2 is an important signal molecule for acute inflammation-induced cellular proliferation, and that ERK5 may participate in the development of chronic glomerular lesions in GN.
MAPK in glomerular cells
Ang II stimulates ERK1/2 activation via NADPH oxidase-dependent reactive oxygen species (ROS) production in cultured rat MCs (Gorin et al., 2004 (Urushihara et al., 2010) . These findings suggest that Ang II directly induces ERK5 phosphorylation via NADPH in an oxidase-independent manner, and that ROS and Ang II could each induce ERK5 phosphorylation in MCs through different signaling pathways.
ERK5-specific knockdown in cultured rat mesangial cells (MC)
To examine the endogenous function of ERK5 in MCs, we used the small interfering (si) RNA technique for ERK5 gene silencing. MCs were transiently transfected with a mixture of three ERK5-specific siRNAs, using the lipofection method. After incubation in a low-serumcontaining medium (5% FBS) for 18 hours, the serum concentration was adjusted to that of complete medium and the cells were cultured further. A non-silencing siRNA that did not target any known mammalian genes was used as a negative control. The transfection efficiency, determined under the same experimental conditions by counting the number of fluorescently labeled siRNA-transfected cells using a fluorescence microscope, was ~80%. Inhibition of ERK5 expression was verified by quantitative real-time PCR and western blot analysis. Further, we evaluated the viability of siRNA-transfected cells cultured for 24 hours in serum-free medium using the WST-1 assay for determining cell survival rate. The WST-1 assay was performed using a cell counting kit, according to the manufacturer's protocol. Briefly, siRNA-transfected cells grown in 96-well plates were washed with PBS, and 10 L of the WST-1 reagent was added to 100 L of cell culture medium in each well. After incubation for 8 hours, the absorbance of the samples was measured at 450 nm (test) and 690 nm (reference) with a microplate reader. Additionally, we measured the soluble collagen levels in culture supernatants after 24 hours of incubation in serum-free medium using a Sircol collagen assay. This assay measures the total collagen secreted from cultured cells. Briefly, cells were cultured for 24 hours with or without treatment, and supernatants were collected. One milliliter of Sirius red, an anionic dye that specifically reacts with basic side chain groups of collagens, was added to 200 L of the supernatant and incubated with gentle rotation for 30 minutes at room temperature. After centrifugation, the collagen-bound dye was resolublized in 1 mL of 0.5 M NaOH, and the absorbance at 540 nm was measured. Fig. 3 . Effects of Angiotensin II (Ang II) or H 2 O 2 on cell viability and collagen secretion in ERK5 siRNA-transfected MCs. MCs were transfected with non-silencing siRNA (control siRNA) or ERK5-specific siRNA (ERK5 siRNA) and stimulated with Ang II (100 nM) or H 2 O 2 (50 M) after incubation in serum-free medium for 24 hours. Cell viability was evaluated using the WST-1 assay (8 hours; top), and collagen secretion in culture supernatants was evaluated by the Sircol assay (24 hours; bottom). Values are mean +/-SD. *P < 0.05 between groups as indicated.
Cell viability and collagen secretion
Using the WST-1 and Sircol assays, significant concentration-dependent decreases in both cell viability and soluble collagen secretion were observed in ERK5 siRNA-transfected, but not control siRNA-transfected MCs. Next, the effect of oxidative stress and Ang II on ECM accumulation and cell viability, and the involvement of ERK5 in these processes were examined. As seen in Fig. 3 , Ang II and H 2 O 2 significantly increased both cell viability and soluble collagen secretion in control siRNA-transfected MCs (P < 0.05). Transfection of ERK5 siRNA significantly reduced Ang II-or H 2 O 2 -induced increases in MC viability and collagen secretion compared to control siRNA transfection (P < 0.05). Many studies have demonstrated that the ERK5 pathway controls cellular processes, such as proliferation, survival, differentiation, and ECM metabolism in pathophysiological conditions (Chang and Karin, 2001; Kyriakis and Avruch, 2001; Nishimoto and Nishida, 2006) . We investigated the involvement of MC ERK5 expression in chronic progressive GN using in vitro and in vivo studies. We found that both cell viability and soluble collagen secretion were induced by Ang II or H 2 O 2 in control MCs. These changes were significantly inhibited in ERK5 siRNA-transfected MCs, suggesting a possible role for ERK5 expression in the sustained MC proliferation and pathological ECM accumulation observed in progressive GN. Furthermore, the data obtained from the treatment of GN rats with ARB indicate that Ang II is an inducer of MC ERK5 phosphorylation in vivo, and support the involvement of Ang II-induced ERK5 phosphorylation in progressive glomerular lesions. In general, the repair of proliferative GN-induced damage requires the regression of the proliferated glomerular cells by apoptosis and the appropriate removal of the accumulated pathological ECM (Shimizu et al., 1995) . Based on our results, the activation of an ERK5 signal may not only induce prolonged MC survival, but also enhance the secretion of pathological collagen I within damaged glomeruli, thereby contributing to the development of progressive GN.
Conclusion
The present study has revealed that phospho-ERK1/2 and phospho-ERK5 expression in the glomeruli are markedly increased in an experimental model of progressive GN. Glomerular ERK1/2 activation seems to play an important role in acute inflammation-induced cellular proliferation in the development of GN. Furthermore, the enhancement of ERK5 phosphorylation by Ang II appears to be linked to the increased MC viability and pathological ECM accumulation in the chronic glomerular lesions in GN (Fig. 4) . We, therefore, propose that the controlled regulation of glomerular ERK1/2 and ERK5 activation could provide the basis for an effective therapeutic strategy for preventing the progression of GN. 
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